Is stem cell therapy for Long COVID worth it?
Outside an authorised trial, current evidence does not support paying for a cell or exosome product as established long-COVID treatment. Independent review should assess alternative diagnoses, symptom management, pacing or rehabilitation suitability and protocol uncertainty.
How stem cells are studied for Long COVID
Long COVID is a heterogeneous post-infectious condition with combinations of fatigue, post-exertional symptom exacerbation, breathlessness, cognitive, autonomic, sleep, pain and other symptoms. Cell and exosome proposals invoke immune or endothelial modulation, but the syndrome's heterogeneity means a broad mechanism does not establish benefit for an exact product or patient group.
Am I a candidate? → · Long COVID: full overview → · Long COVID cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.